Jason Gluck, DO
Advanced Heart Failure and Transplant Cardiology · Hartford, CTNPI 1487807715
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,363 of the $37,961 with a category attached, or 72.1%. Abbott accounts for 87.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $12,758 and has fallen 81.3% since, to $2,384 in 2025.
Across 169 payments — averaging $224.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$33K
- Medtronic$3K
- Arthrex$406
- Kairos Surgical Inc$301
- La Jolla Pharmaceutical Company$278
- Abiomed$249
- plus $544 from 10 others
Across 6 payments — averaging $21,723 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$130K
What the payments were for
- Consulting fees$27,36372%
- Travel & lodging$4,48612%
- Food & beverage$6,07116%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 109 | $33,105 |
| Medtronic(2 entities) | 23 | $3,079 |
| Arthrex | 4 | $406 |
| Kairos Surgical Inc | 6 | $301 |
| La Jolla Pharmaceutical Company | 3 | $278 |
| Abiomed | 3 | $249 |
| Inari Medical, Inc. | 1 | $149 |
| Boehringer Ingelheim | 5 | $95 |
| Pfizer | 4 | $60 |
| Novartis | 2 | $59 |
| Amgen | 3 | $58 |
| Impulse Dynamics (USA) Inc. | 1 | $33 |
| Johnson & Johnson | 2 | $32 |
| Merck | 1 | $24 |
| AstraZeneca | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CentriMag$12,375
- CARDIOMEMS$7,283
- HeartMate II LVAS$4,751
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$2,680
- CardioMEMS HF System$2,263
- HeartMate 3 Left Ventricular Dev$1,500
- VITALFLOW CONSOLE$1,327
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$564
- FLOWTRIEVER CATHETER, S$149
- CT THROMBECTOMY SYSTEM KIT$149
- AURORA EV-ICD MRI SURESCAN$149
- Micra$143
- GIAPREZA$133
- Impella$132
- AZURE XT DR MRI SURESCAN$124
- HeartWare HVAD$104
How this compares
Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $494,273 |
| JardianceEmpagliflozin | 71 | $66,368 |
| EntrestoSacubitril/Valsartan | 58 | $55,716 |
| Metoprolol Succinate | 42 | $663 |
| Torsemide | 22 | $450 |
| Furosemide | 23 | $251 |
| Carvedilol | 13 | $156 |
| Spironolactone | 32 | $112 |
| Amiodarone Hcl | 11 | $95 |
| Losartan Potassium | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $60 | $494,27314 claims |
| Boehringer IngelheimJardiance | $95 | $66,36871 claims |
| NovartisEntresto | $59 | $55,71658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Hartford
- Abhishek JaiswalHartford$48K
- Andrew ScatolaHartford$36K
- Sara TabtabaiHartford$9K
- Jennifer BellHartford$3K
- Xingchen MaiHartford$3K
- Peter VlismasHartford$2K
- Joseph RadojevicHartford$343
- Nikhil SikandNew Haven$29K
- Katherine ClarkNew Haven$12K
- Michael ChenNew Haven$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.